Medical
-
Tonix Pharmaceuticals announced that Massachusetts General Hospital has initiated a Phase 1 trial called FOCUS to evaluate Tonix’s TNX-1900 and TNX-2900 oxytocin nasal sprays in patients with arginine-vasopressin deficiency (central diabetes insipidus). The FOCUS study… Read more . . .
-
GSK has announced that a Phase 3 trial comparing an HFA-152a formulation of Ventolin salbutamol (albuterol) MDI to the currently marketed HFA-134a formulation demonstrated therapeutic equivalence. The company also said that safety of the LGWP propellant… Read more . . .
-
US-based biotech Eradivir announced that a Phase 1/2a trial of its EV25 intranasal antiviral for the treatment of influenza demonstrated that a single 300 mg dose resulted in a significant reduction in lower respiratory tract… Read more . . .
-
Orexo announced that the US Biomedical Advanced Research and Development Authority (BARDA) has awarded the company $8 million to support the development of OX390, a new chemical entity formulated for nasal delivery for the reversal… Read more . . .
-
Tonix Pharmaceuticals has announced plans for a Phase 2 trial of its TNX-2900 intranasal magnesium-potentiated oxytocin in patients with Prader-Willi syndrome (PWS). According to Tonix, the FDA has already cleared the company’s IND for a… Read more . . .
-
Acadia Pharmaceuticals has announced that the Phase 3 COMPASS PWS trial of ACP-101 carbetocin nasal spray in Prader-Willi syndrome patients with hyperphagia failed to meet any of its endpoints, including the primary endpoint of change… Read more . . .
-
Nano PharmaSolutions and CDMO Mikart have announced limited data from an ongoing Phase 1 trial of Nano PharmaSolutions’ NT-301 apomorphine nasal powder, which is in development for the treatment of OFF episodes in Parkinson’s disease.… Read more . . .
-
Phase 2 study finds azelastine nasal spray significantly reduced SARS-CoV-2 and rhinovirus infection
Saarland University announced that the Phase 2 CONTAIN study of azelastine nasal spray as a prophylactic against SARS-CoV-2 demonstrated a significant reduction in SARS-CoV-2 infection and also a reduction in rhinovirus infection for subjects using… Read more . . .
-
SpliSense has announced results from the Phase 2 SPL84-002 study of SPL84 inhaled antisense oligonucleotide (ASO) for the treatment of people with cystic fibrosis who carry the 3849+10 Kb C->T mutation in the CFTR gene. The… Read more . . .
-
According to SoftOx Solutions, the company intends to conduct a Phase 1 proof-of-concept dose escalation study of SoftOx inhalation solution (SIS) in cystic fibrosis patients as part of a refocus away from development of SIS… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland